EUCTR2011-001790-41-GB进行中（未招募）不适用
A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imatinib. - AB11002 - Second line of treatment for GIST
AB Science0 个研究点目标入组 350 人开始时间: 2013年5月14日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient with histological proven metastatic GIST or non-operable locally advanced GIST
- •2. Patient with measurable tumor lesions with longest diameter =(greater than or equal to) 20 mm using conventional techniques or = 10 mm with spiral CT scan according RECIST 1.1
- •3. Patient with C-kit (CD117) positive tumour detected immuno-histochemically
- •4. Patient after at least one progression with imatinib at a dose up to 800 mg. Progression is defined as a RECIST 1.1 and/or CHOI disease progression while receiving imatinib treatment.
- •5. Patient with ECOG = 2
- •6. Patient with adequate organ functions:
- •Absolute neutrophils count (ANC) = 1.5 x 109/L
- •Haemoglobin = 10 g/dL
- •Platelets (PTL) = 75 x 109/L
- •AST and ALT = 3x ULN (= 5 x ULN in case of liver metastases)
- •Gamma GT < 2.5 x ULN (< 5 x ULN in case of liver metastases)
- •Bilirubin = 1.5x ULN (= 3 x ULN in case of liver metastases)
- •normal creatinine or if abnormal creatinine, creatinine clearance = 50 mL/min (Cockcroft and Gault formula)
- •Albumin > 1 x LLN
- •Proteinuria < 30 mg/mL (1+) on the dipstick. If proteinuria is = 1+ on the dipstick, 24 hours proteinuria must be < 1.5g/24 hours
- •7. Patient with life expectancy > 3 months
- •8. Male or female patient, age >18 years
- •9. Patient with a BMI > 18 kg/m² and weighing at least 40kg
- •10. Contraception:
- •Female patient of childbearing potential (entering the study after a menstrual period and who have a negative pregnancy test), who agrees to use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.
- •Male patient with a female partner of childbearing potential who agrees to use a highly effective method of contraception and an acceptable method of contraception by his female partner during the study and for 3 months after the last treatment intake or who agrees to use an acceptable method of contraception and a highly effective method of contraception by his female partner during the study and for 3 months after the last treatment intake.
- •Highly effective methods of contraception include:
- •- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
- •- Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable
- •- Intrauterine device (IUD)
- •- Intrauterine hormone-releasing system (IUS)
- •- Bilateral tubal occlusion
- •- Vasectomized male (azoospermia assessed medically)
- •- Sexual abstinence (Its reliability should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient)
- •Acceptable methods of contraception include:
- •- Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
- •- Male or female condom with or without spermicide
- •- Cap, diaphragm, or sponge with spermicide
- •11. Patient able and willing to comply with study procedures as per protocol
- •12. Patient able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures.
- •13. Patient able to understand the patient card and to follow the patient card procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Numb
排除标准
- •1. Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ.
- •2. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
- •3. Patient presenting with cardiac disorders defined by at least one of the following conditions:
- •Patient with recent cardiac history (within 6 months) of:
- •- Acute coronary syndrome
- •- Acute heart failure (class III or IV of the NYHA classification)
- •- Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- •Patient with cardiac failure class III or IV of the NYHA classification
- •Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- •Syncope without known aetiology within 3 months
- •Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •4. Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •5. Pregnant, or nursing female patient
- •For the QT/QTc study
- •1. Patients with a marked prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval > 450 milliseconds)
- •2. Patient wih a history of additional risk factors for torsades de pointe (e.g. heart failure, hypokalemia, family history of Long QT Syndrome)
- •3. Patients using concomitant medications that prolong the QT/QTc interval (the list of medications is provided in the section concomitant treatments”)
- •Previous treatment
- •1. Known hypersensitivity to sunitinib or masitinib or to any of the excipients
- •2. Patient previously treated with a dose of imatinib > 800 mg
- •3. Previous treatment with sunitinib or kinase inhibitor other than imatinib
- •1. Treatment with any investigational agent within 4 weeks prior to baseline
- •2. Previous imatinib treatment should be permanently discontinued within 4 days prior randomisation and patient should have recovered from potential toxicity related to imatinib
研究者
相似试验
进行中（未招募）
不适用
A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor resistant to imatinibGastrointestinal stromal tumor resistant to imatinibMedDRA version: 14.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001790-41-FRAB Science210
进行中（未招募）
不适用
This study aims to compare the efficienty and safety of masitinib at a dose of 12 mg/kg/dag to those of a standard treatment for GIST: sunitinib (Sutent) at a dose of 50 mg/day for 4 consecutive weeks followed by 2 weeks without medication. Masitinib and sunitinib will be administred untill disease progression in patients with GIST resitant to imatinib (Glivec)stromal gastrointestinal cancer (GIST)MedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 100000004864EUCTR2011-001790-41-BEAB Science208
进行中（未招募）
1 期
A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imatinibGastrointestinal stromal tumor after progression with imatinibMedDRA version: 17.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 100000004864EUCTR2011-001790-41-ITAB Science208
进行中（未招募）
1 期
This study aims to compare the efficiency and safety of masitinib at a dose of 12 mg/kg/dag to those of a standard treatment for GIST: sunitinib (Sudent) at a dose of 50 mg/day for 4 consecutive weeks followed by weeks without medication. Masitinib and sunitinib will be administred untill disease progression in patients with GIST after receiving imatinib (Glivec)Stromal gastrointestinal tumor (GIST)MedDRA version: 17.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 100000004864EUCTR2011-001790-41-GRAB Science208
招募中
3 期
A prospective, multicenter, randomised, open-label, active controlled, 2 parallel groups, phase 3 study to compare the efficay and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imitinibgastro-intestinal stomal tumor (GIST)1001799010017991NL-OMON44774AB Science30